

## 台灣胰臟醫學會第七屆第一次會員大會暨學術研討會

會議時間：107 年 8 月 25 日 (星期六) 13:55~18:10

會議地點：臺北文華東方酒店 B2 文華貳廳 (地址：台北市敦化北路 158 號)

主辦單位：台灣胰臟醫學會、國泰綜合醫院

◎ 活動報名費：會員免費；非會費 3,000 元 (當天於會場繳交)

Time	Topic	Speaker	Moderator
13:00~	Registration		
13:55~14:00	Opening Remarks	李嘉龍 理事長 胰臟醫學會	
14:00~14:50	Pancreas Transplantation	石宜銘 醫師 台北榮總 一般外科	葉大森 醫師 林口長庚 一般外科
14:50~15:40	Acute Pancreatitis Taiwan Consensus	廖偉智 醫師 臺大醫院 胃腸肝膽科	林肇堂 醫師 輔仁大學 醫學院院長
15:40~16:00	Coffee Break & 第七屆第一次會員大會暨選舉		
16:00~16:40	The Role of Endoscopy in Pancreatic Mass	郭雨庭 醫師 臺大醫院 胃腸肝膽科	王秀伯 醫師 臺大醫院 胃腸肝膽科
16:40~17:20	Metastatic Pancreatic Cancer- Current Status, Unmet Needs and Future Perspective	白禮源 醫師 中國附醫 血液腫瘤科	許駿 醫師 臺大醫院 腫瘤醫學部
17:20~18:00	Local Experience of Onivyde in pancreatic adenocarcinoma	沈延盛 醫師 成大醫院 一般外科	陳立宗 醫師 國衛院 癌研所
18:00~18:10	Closing	李嘉龍 理事長 胰臟醫學會	

學會教育積分：(申請中)

台灣外科醫學會、台灣內科醫學會、台灣消化系外科醫學會、台灣消化系內視鏡醫學會、  
台灣消化系醫學會、中華民國醫用超音波醫學會、中華民國放射線醫學會、中華民國癌症醫學會  
台灣內視鏡外科醫學會 10 分

# CURRICULUM VITAE

Yi-Ming Shyr, MD, FACS

3/8/2018



**Education:** M.D., 1977 - 1984, National Yang Ming Medical College

**E-mail:** ymshyr@gmail.com

## Current Position

1. Chief  
Division of General Surgery, Department of Surgery  
Taipei Veterans General Hospital
2. Professor of Surgery  
National Yang Ming University

## Academic, Hospital and Association Appointments

- 2012-1-16 - present: Chief, Division of General Surgery, Department of Surgery  
Taipei Veterans General Hospital
- 2000-8-1 - present: Professor of Surgery, National Yang Ming University
- 1996 - 2000: Associate professor of Surgery, National Yang Ming University
- 1991 - present: Attending Surgeon, Division of General Surgery, Department of Surgery  
Veterans General Hospital-Taipei
- 1990 - 1996: Instructor of Surgery , National Yang Ming University
- 1986 - 1990: Teaching Assistant, National Yang Ming Medical College
- 2006- 2008: Deputy Secretary General (副祕書長) of Taiwan Surgical Association
- 2005 - 2008: Director (理事)The Chinese Association of Transplantation
- 2003 - 2006: Councilor (監事) of Taiwan Pancreas Society
- 2006 - 2009: Director (理事) of Taiwan Pancreas Society
- 2008 - 2010: Deputy Editor of Formosal Journal of Surgery
- 2008 - 2011: Director (理事)The Chinese Association of Transplantation
- 2009 – 2012:Director (理事) of Taiwan Pancreas Society
- 2010 – 2012:Director (理事) of Taiwan Surgical Society of Gastroenterology
- 2012 – 2014:Director (理事) of Taiwan Surgical Society of Gastroenterology

2012 – 2015: Director (理事) of Taiwan Pancreas Society  
2014 – 2016: Director (理事) of Taiwan Surgical Society of Gastroenterology  
2014 - 2017: Director (理事) The Chinese Association of Transplantation  
2015 – 2018: Director (理事) of Taiwan Pancreas Society  
2016 – 2018: Executive Director (常務理事) of Taiwan Surgical Society of Gastroenterology  
2017 - 2020: Executive Director (常務理事) of The Chinese Association of Transplantation

## **Memberships**

1987 - 1993: Formosa Medical Association  
1989 - present: The Society of Ultrasound in Medicine, R.O.C.  
1990 - present: The Surgical Association, R.O.C.  
1991 - present: Chinese Society of Clinical Oncology  
1991 - present: Collegium Internationale Chirurgiae Digestivae (CICD)  
1991 - present: The Surgical Society of Gastroenterology, R.O.C.  
1992 - present: The Digestive Endoscopic Society of the Republic of China  
1992 - present: The Surgical Endocrine Association, R.O.C.  
1993 - present: The Chinese Association of Endoscopic Surgery  
1997 - present: International Hepato-Pancreato-Biliary Association (IHPBA)  
1998 - present: International Gastro-Surgical Club (IGSC)  
1998 - present: Fellow of American College of Surgeons (FACS)  
2000 – present: The Chinese Association of Transplantation  
2000 – present: Taiwan Pancreas Society

## **Editorial Board Member**

2015 – present: International Journal of Digestive Diseases

## **Medical Training**

1982 – 1984: Intern, Veterans General Hospital-Taipei and Taichung  
1984 – 1986: Army Officer of Medicine in the Army 3388 Dispensary  
1986 – 1990: Resident, Department of Surgery, Taipei Veterans General Hospital  
1990 – 1991: Chief Resident, Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital  
1992 – 1994: Surgical oncology fellow in Surgical Oncology Training Program of Academia - Taipei Veterans General Hospital, R.O.C., 1992 - 1994, including Visiting Professors: John E. Olson, Harold J. Wanebo, Blake Cady, Stanley R. Friesen, Rosemary B. Duda, Michael T. Lotze, Masatoshi Makuuchi, Frederick L. Greene, Benjamin Kim, Herbert C. Hoover, Jr., M. Bernadette Ryns, Alfred S. Ketcham, Monica Morrow, V. Craig Jordan, Robert M. Beazley  
1995 Nov. -1996 Nov.: Surgical Fellow (GI Lab. and Clinical) University of Kansas Medical Center, U.S.A.  
1999 Feb. - Aug.: Transplant Fellow in University of Wisconsin Hospital and Clinics (Prof. Sollinger), Madison, U.S.A.

- 2007 May - June: Transplant Fellow in University of Minnesota Medical Center, Fairview  
(**Prof. Sutherland**), Minneapolis, U.S.A.
- 2015 May 20 ~ 21: Laparoscopic surgery observer in Samsung Medical Center, Korea (**Prof. Jin Seok Heo**) and Asan Medical Center, Korea (**Prof. Song Cheol Kim**)
- 2015 Nov. 16 ~ 19: Robotic surgery observer in Ruijin Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, China. (**Prof. Peng CH**)
- 2016 Dec. 10~17: Robotic surgery observer in Piza University Hospital, Italy (**Prof. Ugo Boggi**)
- 2017 Aug. 1 ~ 4: Laparoscopic surgery observer in Zhejuang Provincial People's Hospital, China (**Prof. Yiping Mou**)
- 2017 Oct. 26 ~ 28 Robotic pancreatic surgery observer in The General Hospital of People's Liberation Army(301 hospital), China (**Prof. Rong Liu**)

### **Award and Honor**

- 1992 Award of Excellent Teaching, Taipei Veterans General Hospital
- 1997 Award of Medical Technique Innovation, Taipei Veterans General Hospital
- 2000 Award of Excellent Teaching, Taipei Veterans General Hospital
- 2005 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2006 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2007 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2009 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2009 Award of Excellent Teaching, Taipei Veterans General Hospital
- 2009 Great Achievement Award of Innovative Medical Techniques and Services at the 50<sup>th</sup> Anniversary of Taipei Veterans General Hospital (台北榮民總醫院五十週年院慶創新性醫療技術與服務重大成就獎)
- 2009 Award of Taipei Medical Association(台北醫師公會杏林獎)
- 2010 Award of Excellent doctor, Veterans Affairs commission, Executive Yuan, R.O.C (輔導會各級醫療及安養機構優良醫師)
- 2011 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2012 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2012 廉政楷模, Taipei Veterans General Hospital
- 2013 Award of Excellent Teaching for Interns, Taipei Veterans General Hospital
- 2014 Best Poster Oral Award of the 11th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA World Congress 2014) at Seoul, Korea
- 2017 Award of Dedication to Medical Education, Taipei Veterans General Hospital (台北榮民總醫院 醫學教育奉獻獎)
- 2017 Copper Award of Symbol of national Quality, Safety and Quality (SNQ國家品質標章銅獎)

# 胰臟移植

石宜銘 王心儀 陳世欽

台北榮民總醫院 國立陽明大學 一般外科

胰臟移植是第一型糖尿病(type I DM, IDDM, juvenile onset DM)目前最好、也是最可靠能永久治癒的方法之一。胰臟雖然不是維生命的必要器官(Pancreas is not a vital organ)，也就是說沒有胰臟或胰臟功能重度障礙的人，只要靠胰島素(insulin)注射及服用高單位胰消化酵素(pancreatic enzyme)，仍然可以活下去；但重度糖尿病卻是引起心臟病、中風、尿毒症、失明等可怕疾病的元兇。如同尿毒症需長期洗腎的病人一樣，沒有胰臟或胰臟功能重度障礙的患者也需終生在"血糖、胰島素、飲食"上奮鬥，不但生活品質大大的降低，其生命也往往因長期重度糖尿病所帶來的合併症而提早結束。因此胰臟移植雖然沒有心、肝或肺移植手術那麼迫切需要及危險，但在積極的預防或改善重度糖尿病的合併症所帶來的生命威脅及增進生活品質上卻有其重大的意義。台北榮民總醫院於2007年8月31日成為"第一個獲得衛生署認可具有資格進行胰臟移植、屍體胰臟摘取手術的醫院及醫師"。台北榮民總醫院自2003年9月19日起至2018年6月19日止已完成143例的人體異體胰臟移植，胰移植手術成功率96%。胰臟移植目前在台灣仍屬少見及困難度較高的手術，移植的胰臟一年、五年及十年的存活率分別為98.9%、87.2%及67.8%，而病人一年、五年及十年的存活率分別為96.9%、91.5%及91.5%。**胰臟移植的種類**

依據糖尿病的合併症的嚴重程度，腎功能的好壞，器官來源問題及少數特殊原因(如全胰切除)，胰臟移植可分成三類：1. 胰腎臟同時(SPK = simultaneous pancreas and kidney)移植，2. 腎後胰臟(PAK = pancreas after kidney)移植，3. 單獨胰臟(PTA = pancreas transplant alone)移植。根據國際胰臟移植註冊資料，88%的胰臟移植為胰腎臟同時移植(SPK)，10%的胰臟移植為腎後胰臟移植(PAK)，2%的胰臟移植為單獨胰臟移植(PTA)。胰腎臟同時移植(SPK)一年的成功率(1-year graft survival)為85%，胰臟移植為腎後胰臟移植(PAK)為78%，單獨胰臟移植(PTA)為76%。這個預後的差別也許是因為胰腎臟同時移植(SPK)的患者可由腎功能(serum creatinine)變化而及早得知胰排斥，且可用腎切片來監測胰排斥的診斷和治療效果。

## 胰臟移植的適應症

胰臟移植主要的對象為第一型糖尿病(type I DM, IDDM)患者。第一型糖尿病患者經過30年後，約30%會產生視網膜病變(retinopathy)，40%產生腎病變(nephropathy)，60%產生神經病變(neuropathy)。除此之外，糖尿病也是引起心臟血管疾病元兇之一。至目前為止，胰臟移植能夠提供第一型糖尿病患者免除胰島素注射而能達到近乎生理的正常血糖控制，進而改善或減緩糖尿病的合併症。胰臟移植是解決了第一型糖尿病患者胰島素注射的不便及改善或減緩其合併症。因長期服用抗排斥藥的不便及其潛在的副作用，因此在考慮胰臟移植的同時，也要考慮長期服用抗排斥藥所帶來的另一問題。基於這個理由，並非所有第一型糖尿病患者都需馬上考慮胰臟移植手術，而只有第一型糖尿病患者已產生合併症(腎病變，視網膜病變，神經病變)或少數特殊原因才值得考慮胰臟移植。

## 臺灣胰臟移植適應症：

1. 第一型糖尿病或低胰島素分泌患者，併有糖尿病合併症產生，如腎病變、視網膜病變、神經病變、心腦血管病變等者
2. 第一型糖尿病或低胰島素分泌患者，常因血糖過低引發生命威脅者。

3. 第一型糖尿病或低胰島素分泌患者，因血糖控制不易產生求學、就業及日常生活困難者。
4. 第二型糖尿病患者，已使用胰島素注射治療，且合併有腎衰竭現象者，但胰島素注射量需少於 1.5 units/kg/day，且無其他器官嚴重疾病。

## 履歷

姓名	廖偉智	
生日	1971 / 10 / 27	
職稱	主治醫師/臨床助理教授	
連絡電話	(02)23123456ext63356	
E-MAIL	david.ntuh@gmail.com	
學歷	國立台灣大學醫學系醫學士 (1996)	
	國立台灣大學流行病學研究所碩士(2009)	
	國立台灣大學流行病學與預防醫學研究所博士(2014)	
資歷	國立台灣大學附設醫院內科部住院醫師(1998~2001)	
	國立台灣大學附設醫院內科部肝膽腸胃科訓練醫師(2001~2003)	
	國立台灣大學附設醫院內科部專任主治醫師(2005~迄今)	
	台灣大學醫學院醫學系內科臨床助理教授(2010~迄今)	
榮譽記錄	1. 2012 American Society for Gastrointestinal Endoscopy (ASGE) Ambassador 2. 2012-2014 Outstanding Reviewer for GIE: Gastrointestinal Endoscopy 3. 2014 年臺大醫院年輕優秀研究傑出獎	
特殊證照	醫師執照、內科專科醫師、消化系內科專科醫師、內視鏡專科醫師、教育部部定助理教授	
專長	內科學、消化醫學、內視鏡學、流行病學	
著作	1. <u>Liao WC</u> , Tu YK, Wu MS, Lin JT, Wang HP, Chien KL. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. The BMJ 2015 Jan;349:g7371. 2. <u>Liao WC</u> , Wang HP. ERCP in acute cholangitis. In: ERCP the fundamentals, 2nd edition. Cotton PB, Leung J (editors). Wiley Blackwell 2015.	

著  
作  
(續上頁)

3. Lin HH, Chang HY, Chiang YT, Wu MS, Lin JT, Liao WC (corresponding author). [Smoking, drinking, and pancreatitis: a population-based cohort study in Taiwan.](#) Pancreas 2014 Oct;43(7):1117-22.
4. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. The Lancet Oncology 2013 Oct;14(11):1095-103.
5. Liao WC, Leung JW, Wang HP, Lin JT, Wilson RE, Lim BS, Leung FW. Coached practice using ERCP mechanical simulator improves trainees' ERCP performance: a randomized controlled trial. Endoscopy 2013 Oct;45(10):799-805.
6. Liao WC, Tu YK, Wu MS, Wang HP, Lin JT, Leung JW, Chien KL. Balloon dilation with adequate duration is safer than sphincterotomy for extracting bile duct stones: a systematic review and meta-analyses. Clinical Gastroenterology & Hepatology 2012 Oct;10(10):1101-9.
7. Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, Lin YL, Lin JT. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clinical and Translational Gastroenterology 2012 Sep;3:e22.
8. Liao WC, Lee CT, Chang CY, Leung JW, Chen JH, Tsai MC, Lin JT, Wu MS, Wang HP. Randomized trial of 1-minute versus 5-minute endoscopic balloon dilation for extraction of bile duct stones. Gastrointestinal Endoscopy 2010 Dec;72(6):1154-62.
9. Liao WC, Chiu HM, Chen CC, Lee YC, Wu MS, Lin JT, Wu AS, Wang HP. A Prospective evaluation of feasibility of primary screening with unsedated colonoscopy. Gastrointestinal Endoscopy 2009 Oct;70(4):724-31.
10. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 2009 May;38(4):422-6.
11. Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS. Serum interleukin-6 level but not genotype predicts survival after resection in stage II and III gastric carcinoma. Clinical Cancer Research 2008 Jan;14(2):428-34.
12. Liao WC, Huang SP, Wu MS, Lin JT, Wang HP. Comparison of endoscopic papillary balloon dilatation and sphincterotomy for lithotripsy in difficult sphincterotomy. Journal of Clinical Gastroenterology 2008 Mar;42(3):295-9.
13. Liao WC, Wang HP, Chiu HM, Chang CY, Lin JT. Multiple hepatic nodules: rare manifestation of Clonorchiasis. Journal of Gastroenterology and Hepatology 2006 Sep;21(9):1497-500.



著作  
(續上頁)

14. Han ML, Lin HF, Liu KL, Lee TH, Liao WC (corresponding author). Anaerobic bacteremia in a patient with necrotizing pancreatitis. *GUT* 2008 Nov;57(11):1530, 1553.
15. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L, Frulloni L, Go VL, Gress TM, Kim MH, Kawa S, Lee KT, Lerch MM, Liao WC, Löhr M, Okazaki K, Ryu JK, Schleinitz N, Shimizu K, Shimosegawa T, Soetikno R, Webster G, Yadav D, Zen Y, Chari ST. [Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.](#) *Gut* 2013 Dec;62(12):1771-6.
16. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. *The BMJ* 2013 Oct;347:f6008.
17. Huang HY, Cheng YY, Liao WC, Tien YW, Yang CH, Hsu SM, Huang PH. [SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer.](#) *PLoS One* 2012 Dec;7(12):e48637.
18. Tseng PH, Lee YC, Chiu HM, Chen CC, Liao WC, Tu CH, Yang WS, Wu MS. [Association of diabetes and HbA1c levels with gastrointestinal manifestations.](#) *Diabetes Care* 2012 May;35(5):1053-60.
19. Kamisawa T, Kim MH, Liao WC, Liu Q, Balakrishnan V, Okazaki K, Shimosegawa T, Chung JB, Lee KT, Wang HP, Lee TC, Choudhuri G. Clinical characteristics of 327 Asian patients with autoimmune pancreatitis based on Asian diagnostic criteria. *Pancreas* 2011 Mar;40(2):200-5.
20. Tseng PH, Chen CC, Chiu HM, Liao WC, Wu MS, Lin JT, Lee YC, Wang HP. Performance of narrow band imaging and magnification endoscopy in the prediction of therapeutic response in patients with gastroesophageal reflux disease. *Journal of Clinical Gastroenterology* 2011 Jul;45(6):501-6.
21. Lee CT, Lee TL, Liao WC, Chang CY, Tai CM, Chiang TH, Tu CH, Tseng WK, Lin JT. Myocardial ischemia during endoscopic retrograde cholangiopancreatography: an overlooked issue with significant clinical impact. *Journal of Gastroenterology and Hepatology* 2010 Sep;25(9):1518-24.

Name: Li-Yuan Bai, M.D., M.M.S., Ph.D.  
E-mail: [lybai6@gmail.com](mailto:lybai6@gmail.com)  
Current Position: Aug. 2005 – present : Doctor, Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan  
Feb. 2017 – present: Professor, China Medical University  
Education and Board: Sep. 1987 – Jun. 1994: School of Medicine, National Yang-Ming University, Taipei, Taiwan  
Mar. 1997: Certification of Educational Commission for Foreign Medical Graduates, USA  
Oct. 2001: Certified Doctor of Internal Medicine  
Nov. 2003: Certified Doctor of Medical Oncology  
Feb. 2004: Member of Taiwan Academy of Hospice Palliative Medicine  
Nov. 2004: Certified Doctor of Hematology  
Jul. 2007: Master of Medical Science, Graduate Institute of Medical Science, China Medical University, Taichung, Taiwan  
Jun. 2011: Ph.D., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan  
Previous Employments: Jun. 1998 - Dec. 2004: Resident doctor, Department of Medicine, Taipei Veterans General Hospital (VGH), Taipei, Taiwan  
Dec. 2004 – Jul. 2005: Visiting staff, Department of Medicine, Yilan Hospital  
Mar. 2008 – May. 2009: Visiting scholar at College of Pharmacy, The Ohio State University, Columbus, OH, USA

#### Publications (selective after 2015)

1. Weng JR\*, Bai LY, Ko HH, Tsai YT. Cyclocommunol induces apoptosis in human oral squamous cell carcinoma partially through a Mcl-1-dependent mechanism. *Phytomedicine* 2018 Jan 15;39:25-32.
2. Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5.
3. Weng JR\*, Bai LY, Lin WY. Identification of a Triterpenoid as a Novel PPAR $\gamma$  Activator Derived from Formosan Plants. *Phytother Res*. 2017 Nov;31(11):1722-1730. doi: 10.1002/ptr.5900.
4. Bai LY, Chiu CF, Chiu SJ, Chu PC, Weng JR. FTY720 induces autophagy-associated apoptosis in human oral squamous carcinoma cells, in part, through a reactive oxygen species/Mcl-1-dependent mechanism. *Sci Rep* 2017 Jul 17;7(1):5600. doi: 10.1038/s41598-017-06047-9.
5. Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR\*. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. *Oncotarget* 2017 Apr 25;8(17):29233-29246. doi: 10.18632/oncotarget.16450

6. Weng JR\*, Bai LY, Lin WY, Chiu CF, Chen YC, Chao SW, Feng CH. A Flavone Constituent from *Myoporum bontioides* Induces M-Phase Cell Cycle Arrest of MCF-7 Breast Cancer Cells. *Molecules* 2017 Mar 15;22(3). pii: E472.
7. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Tse-Yen Yang, Aaron M. Sargeant, Li-Yuan Bai\*. Palliative gastrectomy prolongs survival of metastatic gastric cancer patients with normal preoperative CEA or CA19-9 values: a retrospective cohort study. *Gastroenterol Res Pract* 2016;2016:6846027.
8. Chiu CF, Weng JR, Jadhav A, Wu CY, Sargeant AM, Bai LY\*. T315 decreases acute myeloid leukemia cell viability through a combination of apoptosis induction and autophagic cell death. *Int J Mol Sci* 2016 Aug 15;17(8). pii: E1337.
9. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Aaron M. Sargeant, Su-Peng Yeh, Li-Yuan Bai\*. The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. *Springerplus* 2016 Jun 16;5(1):728.
10. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, Chiu SJ, Chiang JH, Weng JR\*. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing strategy. *Sci Rep.* 2016 Jun 9;6:27540. doi: 10.1038/srep27540.
11. Bai LY, Chiu CF, Chu PC, Lin WY, Chiu SJ, Weng JR\*. A triterpenoid from wild bitter melon inhibits breast cancer cells. *Sci Rep.* 2016 Mar 1;6:22419. doi: 10.1038/srep22419.
12. Bai LY, Chiu CF, Kapuriya NP, Shieh TM, Tsai YC, Wu CY, Sargeant AM, Weng JR\*. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. *Eur J Pharmacol* 2015 Dec;769:287-296.
13. Chiou TJ, Chang YF, Wang MC, Kao CW, Lin HY, Chen TY, Hsueh EJ, Lan YJ, Sung YC, Lin SF, Bai LY, Chen CG\*. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. *Transl Res* 2015 Sep 30. pii: S1931-5244(15)00329-1. doi: 10.1016/j.trsl.2015.09.005.
14. Li-Yuan Bai, Chang-Fang Chiu, Shih-Jiuan Chiu, Yu-Wen Chen, Jing-Lan Hu, Chia-Yung Wu, and Jing-Ru Weng\*. Alphitolic acid, an anti-inflammatory triterpene, induces apoptosis and autophagy in oral squamous cell carcinoma cells, in part, through a p53-dependent pathway. *J Funct Foods* 2015;18:368-78.
15. Hung-Jen Chen, Kuo-Yang Huang, Guan-Chin Tseng, Li-Hsiou Chen, Li-Yuan Bai, Shinn-Jye Liang\*, Chih-Yen Tu, Richard W. Light. Diagnostic pitfalls of discriminating lymphoma-associated effusions. *Medicine (Baltimore)* 2015 May;94(17):e800.
16. Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT\*; on behalf of the Taiwan Cooperative Oncology Group. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. *Ann Oncol* 2015 May;26(5):943-9.
17. Tzu-Ting Chen, Chang-Fang Chiu, Tse-Yen Yang, Ching-Chan Lin, Aaron M. Sargeant, Su-Peng Yeh, Yu-Min Liao, Li-Yuan Bai\*. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. *Leuk Res* 2015;39:151-6. (corresponding)

Li-Yuan Bai, M.D., M.M.S., Ph.D.

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. The majority of patients are diagnosed with locally advanced or metastatic disease with a prognosis of short months. The majority of patients present with stage IV disease at diagnosis and these patients have an overall 5-year survival of 3%. Therapeutic options are limited and until recently. The current management of patients with metastatic pancreatic ductal adenocarcinoma is based on systemic chemotherapy. Given the challenges and the rising incidence of PDAC expected to become the second leading cause of cancer-related death by 2030, there is a major unmet need to develop more effective therapies. During more than twenty years, single gemcitabine was the only approved and widely used agent. However, over the last few years, two additional effective regimens have shown clinically meaningful and statistically significant improvement in median survival resulting in a change in first-line treatment selection. FOLFIRINOX and nab-paclitaxel-gemcitabine are standard treatment options in patients with good performance status; both combinations have shown a survival advantage over previously standard gemcitabine monotherapy. Now there was a standard second-line chemotherapy option- liposomal irinotecan. A phase III trial of liposomal irinotecan in combination with fluorouracil and folinic acid in patients with metastatic PDAC, who progressed after gemcitabine-based chemotherapy. As a direct result, the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved the use of liposomal irinotecan in this setting. Recent advances have changed the therapeutic landscape, as clinicians are now able to choose a sequential approach to treatment tailored to the individual patient characteristics.

## Yan-Shen Shan(沈延盛), M.D., PhD.

*Distinguished Professor and Director of Institute of Clinical Medicine  
National Cheng Kung University*

*Director of Clinical Medicine Research Center, National Cheng Kung  
University Hospital*

*Distinguished Professor of Department of Surgery,  
National Cheng Kung University Hospital*



### Education:

2006.11-2007.9 Visiting Scholar of University of Pennsylvania, USA

1998.9-2004.6 PhD of Clinical Medicine, National Cheng Kung University

1988.9-1993.6 MD, School of Medicine, National Cheng Kung University

### Clinical Training:

1981.9-1985.6 Rehabilitation Medicine, School of Medicine, National Taiwan University

1993.7-1998.7 Residency of Surgery, National Cheng Kung University Hospital

### Clinical and Academic Appointments:

1998.8- Department of Surgery, NCKUH

2002.8-2008.7 Clinical assistant professor, of Surgery, NCKUH

2008.8-2012.7 Clinical associate professor of Surgery

2009.10- Convener of UGI Cancer in NCKUH

2010.8-2012.7 Associate professor of Institute of Clinical Medicine, NCKU

2010.9- Chief of Division of Trauma, NCKUH

2012.8- Professor of Institute of Clinical Medicine and Surgery, NCKU

2016.8- Distinguished Professor of Institute of Clinical Medicine, NCKU

### Professional Membership

- Formosan Association of Surgery
- Taiwan Surgical Society of Gastroenterology (member of a council)
- Taiwan Pancreas Society(member of a council)
- Taiwan Society of Endoscopic Surgery (member of a supervisor)
- 中華民國癌症醫學會(腫瘤外科專科醫師 and 指導醫師) (member of a council)
- 台灣代謝及減重外科醫學會(member of a council)
- International Hepato-Pancreato-Biliary Association (M2527)
- International Association of Surgeon and Gastrpenterologists
- The Society for Surgeon of the Alimentary Tract, USA

### Latest Bibliography: (\*: correspondence)(Since 2016, selected)

Book:

Ying-Jui Chao, **Yan-Shen Shan**\*. Laparoscopic Pancreaticoduodenectomy. *In Innovation and diagnosis for pancreatic cancer*. Hiroki Yamaue (ed.), Chap 10; page: 129-145. Springer Singapore 2017.

1. Ya-Chin Hou, Ching-Cheng Hsu, Hui-Ling Tung, Min-Hua Hsieh, Hao-Chen Wang, Yi-Ching Wang, and **Yan-Shen Shan**\*. Rab37 mediates exosomal osteopontin secretion to promote pancreatic cancer metastasis and stemness. (Nat Com 2018 revision)
2. Ching-Wen Yu, Lien-Yu Hung, Chien-Yu Fu, Chih-Hung Wang, Nai-Jung Chiang, Yu-Chun Wang, **Yan-Shen Shan**\*, Gwo-Bin Lee\*. Screening of Peptides Specific to Cholangiocarcinoma Cancer Cells Using an Integrated Microfluidic System and Phage Display Technology. *Microfluid Nanofluid* 2017; 21: 145.
3. Pei-Yi Chu<sup>#</sup>, Shih Sheng Jiang<sup>#</sup>, **Yan-Shen Shan**<sup>#</sup>, Wen-Chun Hung, Ming-Huang Chen, Hui-You Lin, Yu-Lin Chen, Hui-Jen Tsai, Li-Tzong Chen. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and desensitizes pNET to mTOR inhibitors. *Oncotarget* 2017 Oct 9;8(61):103613-103625.(co-first).
4. Tsung-Ming Chang<sup>#</sup>, **Yan-Shen Shan**<sup>#</sup>, Pei-Yi Chu<sup>#</sup>, Shih Sheng Jiang, Wen-Chun Hung, Yu-Lin Chen, Hsu-Chi Tu, Hui-You Lin, Hui-Jen Tsai, Li-Tzong Chen. The regulatory role of aberrant

- Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. *Oncotarget* 2017 Sep 16;8(58):98068-98083. (co-first)
5. **Yan-Shen Shan**, Hui-Ping Hsu, Ming-Derg Lai, Yu-Hsuan Hung, Chih-Yang Wang, Meng-Chi Yen, Yi-Ling Chen. Increased expression of cyclin D1 correlates with poor tumor differentiation and predicts poor prognosis in gastric cancer patients. *Oncol Lett* 2017; 14: 4517-26.
  6. Hao-Chen Wang, Chin-Wang Chen, Chia-Lung Yang, I-Min Tsai, Ya-Chin Hou, Chang-Jung Chen, **Yan-Shen Shan\***. Tumor-Associated Macrophages Promote Epigenetic Silencing of Gelsolin through DNA Methyltransferase 1 in Gastric Cancer Cells. *Cancer Immunology Research* 2017 Aug 23. pii: canimm.0295.2016..
  7. Gopinathan P, Hung LY, Wang CH, Chiang NJ, Wang YC, **Shan YS\***, Lee GB. Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform. *Biomicrofluidics*. 2017 Jul 5; 11(4): 044101.
  8. Shu-Ting Yen, Chih-Jung Wang, Shih-Fang Huang, Su-Chen Hsu, Jeremy C. Ying\*, **Yan-Shen Shan\***. Effectiveness of Trauma Team on Medical Resource Utilization and Quality of Care for Patients with Major Trauma. *BMC Health Services Research* 2017 Jul 24;17(1):505..
  9. Lien-Yu Hung, Nai-Jung Chiang, Wei-Chun Tsai, Chien-Yu Fu, Yu-Chun Wang, **Yan-Shen Shan\***, and Gwo-Bin Lee\*. A microfluidic chip for detecting cholangiocarcinoma cells in human bile. *Sci Rep* 2017 Jun 26;7(1):4248.
  10. Iwashita Y, Hibi T, Ohyama T, Honda G, Yoshida M, Miura F, Takada T, Han HS, Hwang TL, Shinya S, Suzuki K, Umezawa A, Yoon YS, Choi IS, Huang WS, Chen KH, Watanabe M, Abe Y, Misawa T, Nagakawa Y, Yoon DS, Jang JY, Yu HC, Ahn KS, Kim SC, Song IS, Kim JH, Yun SS, Choi SH, Jan YY, **Shan YS**, Ker CG, Chan DC, Wu CC, Lee KT, Toyota N, Higuchi R, Nakamura Y, Mizuguchi Y, Takeda Y, Ito M, Norimizu S, Yamada S, Matsumura N, Shindoh J, Sunagawa H, Gocho T, Hasegawa H, Rikivama T, Sata N, Kano N, Kitano S, Tokumura H, Yamashita Y, Watanabe G, Nakagawa K, Kimura T, Yamakawa T, Wakabayashi G, Mori R, Endo I, Miyazaki M, Yamamoto M. An opportunity in difficulty: Japan-Korea-Taiwan expert Delphi consensus on surgical difficulty during laparoscopic cholecystectomy. *J Hepatobiliary Pancreat Sci*. 2017 Apr; 24(4): 191-198.
  11. Tzeng HT, Tsai CH, Yen YT, Cheng HC, Chen YC, Pu SW, Wang YS, **Shan YS**, Tseng YL, Su WC, Lai WW, Wu LW, Wang YC. Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculation and Metastasis. *Clin Cancer Res*. 2017 May 1; 23(9): 2335-2345.
  12. Hibi T, Iwashita Y, Ohyama T, Honda G, Abe Y, Yoshida M, Miura F, Takada T, Han HS, Yoon YS, Hwang TL, Shinya S, Suzuki K, Umezawa A, Choi IS, Huang WS, Chen KH, Watanabe M, Misawa T, Nagakawa Y, Yoon DS, Jang JY, Yu HC, Ahn KS, Kim SC, Song IS, Kim JH, Yun SS, Choi SH, Jan YY, Sheen-Chen SM, **Shan YS**, Ker CG, Chan DC, Lee KT, Toyota N, Higuchi R, Yamamoto M, Nakamura Y, Mizuguchi Y, Takeda Y, Ito M, Norimizu S, Yamada S, Matsumura N, Tokumura H, Shindoh J, Sunagawa H, Hasegawa H, Rikivama T, Sata N, Kano N, Kitano S, Yamashita Y, Watanabe G, Nakagawa K, Kimura T, Yamakawa T, Wakabayashi G, Endo I, Miyazaki M. The "right" way is not always popular: Comparison of surgeons' perceptions during laparoscopic cholecystectomy for acute cholecystitis among experts from Japan, Korea, and Taiwan. *J Hepatobiliary Pancreat Sci*. 2017 Jan; 24(1): 24-32.
  13. Po-Hsien Huang, Pei-Jung Lu, Li-Yun Ding, Po-Chen Chu, Chih-Chieh Tsao, Wei-Yu Hsu, Bo-Heng Chen, Pei-Rong Gu, Chung-Ta Li, *OSU-NCKU pancreatic cancer study group*, Sally E. Henderson, Samuel, K. Kulp, **Yan-Shen Shan\***, Ching-Shih Chen\*. TGF $\beta$  promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1. *Oncogene* 2017 Apr 20; 36(16):2202-2214.
  14. Tze-Sian Chan, Chung-Chi Hsu, Kok-Tong Tan, Wen-Ying Liao, Shu-Ching Hsu, Vincent Pai, Wei-Yu Chen, **Yan-Shen Shan**, Shenq-Shyang Huang, Kuan-Ying Jiang, Chi-Rong Li, Michael Lee, Gi-Shih Lien, Valerie Weaver, and Kelvin Tsai. Metronomic Chemotherapy Prevents Therapy-induced Stromal ELR+-chemokine Paracrine Signaling for Tumor-initiating Cells. *JEM* 2016 Dec 12; 213(13): 2967-2988.
  15. Iwashita Y, Ohyama T, Honda G, Hibi T, Abe Y, Yoshida M, Miura F, Takada T, Han HS, Yoon YS, Hwang TL, Shinya S, Suzuki K, Umezawa A, Choi IS, Huang WS, Chen KH, Watanabe M, Misawa T, Nagakawa Y, Yoon DS, Jang JY, Yu HC, Ahn KS, Kim SC, Song IS, Kim JH, Yun SS, Choi SH, Jan YY, Sheen-Chen SM, **Shan YS**, Ker CG, Chan DC, Lee KT, Toyota N, Higuchi R, Yamamoto M, Nakamura Y, Mizuguchi Y, Takeda Y, Ito M, Norimizu S, Yamada S, Matsumura N, Tokumura H, Shindoh J, Sunagawa H, Hasegawa H, Rikivama T, Sata N, Kano N, Kitano S, Yamashita Y, Watanabe G, Nakagawa K, Kimura T, Yamakawa T, Wakabayashi G, Endo I, Miyazaki M. What are the appropriate indicators of surgical difficulty during laparoscopic cholecystectomy? Results from a Japan-Korea-Taiwan multinational survey. *J Hepatobiliary Pancreat Sci*. 2016 Sep; 23(9):533-47.
  16. Pan MR, Hsu MC, Luo CW, Chen LT, **Shan YS**, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. *Oncotarget*. 2016 Sep 20;7(38):61136-61151.

17. Liu CT, Chen MH, Chen JS, Chen LT, **Shan YS**, Lu CH, Su YL, Ku FC, Chou WC, Chen YY. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. *Asia Pac J Clin Oncol*. 2016 Dec; 12(4): 396-402.
18. Hung MC, Lai WW, Chen HH, Lee JC, Lin YJ, Hsiao JR, Cheng YM, **Shan YS**, Su WC, Wang JD. Cost effectiveness of cancer treatment in Taiwan. *J Formos Med Assoc*. 2016 Aug 115(8): 609-18.
19. Nai-Jung Chiang, Jang-Yang Chang, **Yan-Shen Shan\***, Li-Tzong Chen,\*.Developing nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. *Expert Opin Pharmacother*. 2016 Jul;17(10):1413-20.
20. Tseng PC, Chen CL, **Shan YS**, Lin CF. An increase in galectin-3 causes cellular unresponsiveness to IFN- $\gamma$ -induced signal transduction and growth inhibition in gastric cancer cells. *Oncotarget*. 2016 Mar 22; 7(12):15150-60.
21. Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, **Yan-Shen Shan\***, Shiu-Feng Huang\*, Li- Tzong Chen\*. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. *Sci Rep* 2016 May 3; 6: 25369.
22. Hao-Chen Wang, Tzu-Ying Li, Ying-Jui Chao, Ya-Chin Hou, Yuan-Shuo Hsueh, Kai-Hsi Hsu, **Yan-Shen Shan\***. KIT exon 11 codons 557-558 deletion mutation promotes liver metastasis through the CXCL12/CXCR4 axis in gastrointestinal stromal tumors. *Clin Cancer Res*. 2016 Jul 15;22(14):3477-87
23. Chen MH, Lin J, Hsiao CF, **Shan YS**, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. *Medicine (Baltimore)*. 2016 Jan; 95(3):e2565.
24. Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, **Yan-Shen Shan**, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F. Blanc, Richard Hubner, C.-F. Chiu, Gilberto Schwartzmann, Jens Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D. Von Hoff, Li-Tzong Chen for the NAPOLI-1 Study Group. Nanoliposomal Irinotecan with 5-Fluorouracil and Leucovorin Increased Survival in Metastatic Pancreatic Cancer After Prior Gemcitabine-based Therapy. *Lancet* 2016, Feb 6;387(10018):545-57.
25. Jeffrey S. Chang, Chia-Rung Tsai, Li-Tzong Chen, **Yan-Shen Shan\***. Investigating the association between periodontal disease and risk of pancreatic cancer. *Pancreas* 2016 Jan;45(1):134-41.
26. Po-Chen Chu, Ming-Chen Yang, Samuel K. Kulp, Santosh B. Salunke, **Yan-Shen Shan**, Chung-Ta Lee, Ming-Derg Lai, Lawrence A. Shirley, Tanios Bekaii-Saab, and Ching-Shih Chen. Regulation of Oncogenic KRAS Signaling via a Novel KRAS-ILK-hnRNPA1 Regulatory Loop in Pancreatic Cancer Cells. *Oncogenes* 2016 Jul 28;35(30):3897-908.